Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

BACKGROUND: EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% of patients with EGFR wild-type are responsive to TKIs, suggesting that other determinants of outcome besides EGFR mutation might exist. We hypothesized that activation of phosphorylated EGFR could be...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wang, Fen, Wang, Shuhang, Wang, Zhijie, Duan, Jianchun, An, Tongtong, Zhao, Jun, Bai, Hua, Wang, Jie
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2012
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548765/
https://ncbi.nlm.nih.gov/pubmed/22901364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-31-65
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky